---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-021981"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:04:54.419582+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara reports Q4 net loss of $10.2M; cash $65.6M; TARA-002 data milestones in 2024

## Summary
- Net loss Q4 2023: $10.2M ($0.90/share); full-year net loss $40.4M ($3.57/share).
- Cash, equivalents & investments $65.6M as of Dec 31, 2023; runway into Q2 2025.
- R&D expenses Q4 $6.4M (up from $5.0M YoY); full-year $25.0M (up from $16.8M).
- Preliminary ADVANCED-1EXP TARA-002 data in NMIBC CIS expected 1H 2024; ADVANCED-2 data in 2H 2024.
- Dosing underway in STARBORN-1 Phase 2 trial of TARA-002 for lymphatic malformations.

## SEC filing metadata
- accession: 0001213900-24-021981
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/0001213900-24-021981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/ea0201584-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-021981
- JSON: https://secwatch.observer/filing/0001213900-24-021981.json
- Plain text: https://secwatch.observer/filing/0001213900-24-021981.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported the full year and fourth quarter ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share, EPS $3.57 per share.
  - Period: the full year and fourth quarter ended December 31, 2023
  - Net income: Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share
  - EPS: $3.57 per share
  - Result: reported results
  source text: Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/0001213900-24-021981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.